Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. has announced the completion of the first visit for the first subject in its Phase I multiple ascending dose study of LAE102, a monoclonal antibody targeting obesity. This study aims to assess the safety and efficacy of LAE102, which has shown promise in pre-clinical models for increasing lean mass and decreasing fat mass, positioning it as a potential breakthrough in weight control therapies.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on developing precision therapies. The company specializes in monoclonal antibodies and aims to provide novel treatment options for conditions such as obesity.
YTD Price Performance: 48.99%
Average Trading Volume: 7,251,517
Technical Sentiment Signal: Strong Sell
For detailed information about 2105 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money